相关实验视频
Updated: Jul 5, 2025

05:52
Prehospital Thrombolysis: A Manual from Berlin
Published on: November 26, 2013
21.9K
完善制药决策支持系统:评估针对抗血栓的算法,以解决与药物相关的问题
Arnaud Potier1, Mathias Ade2, Béatrice Demoré3,4
1Pharmacy, Centre Hospitalier de Lunéville, Lunéville, France apotier@ch-luneville.fr.
European journal of hospital pharmacy : science and practice
|January 17, 2024
概括
将抗血栓药物算法 (PA) 集成到制药决策支持系统 (PDSS) 中,可以有效地检测与药物相关的问题 (DRPs). 这提高了药物干预和患者安全.
科学领域:
- 临床药房 临床药房
- 医疗信息学 医疗信息学
- 药理学 药理学是指药理学的学科.
背景情况:
- 制药决策支持系统 (PDSS) 帮助管理复杂的药物治疗方案.
- 抗血栓剂需要仔细监测,因为它们的治疗指数狭窄和出血风险.
- 与抗血栓药物相关的与药物相关的问题 (DRPs) 可以导致患者的重大伤害.
研究的目的:
- 在PDSS中评估抗血栓学重点制药算法 (PA) 的有效性.
- 确定这些PA对检测DRP和促进药物干预措施的影响.
主要方法:
- 从2019年11月到2023年6月,在两个医疗机构进行了前性观察研究.
- 开发了26种抗血栓特异性PA,并与更广泛的PDSS进行了比较.
- 药剂师审查了系统生成的警报,记录的干预措施和医生接受率.
主要成果:
- 抗血栓PAs确定了PDSS检测到的DRP的很大一部分.
- 药剂师发布了1170项针对抗血栓性警报的干预措施,57.8%被医生接受.
- 包括其他PA在内的PDSS总体结果为3341次干预,接受率为53.4%.
结论:
- 针对抗血栓剂的量身定制的PAs对DRP检测有显著的贡献.
- 将特定的算法集成到PDSS中可以提高药物干预和患者安全.
- PDSS应结合针对抗血栓的算法,以适应患者的需求和补充护理.
更多相关视频
相关概念视频
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
525
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
525
Anticoagulant Drugs: Low-Molecular-Weight Heparins
701
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
701
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Structure-Activity Relationships and Drug Design
726
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
726
Cardiovascular Drugs: Classification based on Therapeutic Indications
2.8K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
2.8K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
432
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
432

